(Q34660100)

3 August 2017

1 reference

title

Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism (English)

1 reference

3 August 2017

0 references

1 reference

1

Stephen M Stahl

1 reference

3 August 2017

6 August 2007

1 reference

The International Journal of Neuropsychopharmacology

3 August 2017

1 reference

3 August 2017

10

1 reference

3 August 2017

5

1 reference

3 August 2017

575-578

1 reference

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

3 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

The circadian basis of winter depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Melatonin in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

inferred from DOI database lookup

7 January 2021

based on heuristic

Atypical antipsychotics: matching receptor profile to individual patient's clinical profile

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of trazodone on the sleep of depressed subjects--a polygraphic study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145707008000

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1461145707008000

0 references

PubMed ID

17681087

1 reference

PubMed ID

17681087